Predict your next investment

Corporation
hovione.com

See what CB Insights has to offer

Investments

2

Partners & Customers

10

About Hovione

Hovione is a pharmaceutical company dedicated to helping customers bring new and off-patent drugs to market.

Hovione Headquarters Location

Loures,

Portugal

+351 21 982 9000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hovione News

Hovione Signs Exclusive License Agreement with JIXING

May 9, 2022

JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization. has entered an exclusive license agreement for a preclinical ophthalmology program, JX08, with Hovione , a leader in spray drying and particle engineering. JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization. “We are excited to partner with Hovione and today’s agreement further strengthens JIXING’s ophthalmology pipeline beyond its current focus on presbyopia and dry eye disease,” said Peter Fong, PhD, board executive director, JIXING. “In addition, this agreement marks a significant step for the company as it highlights its development from a China focused, late clinical-stage biotech to an innovation pioneer with full life cycle development capabilities to reach customers and patients globally.”   “We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione’s leadership position in spray dried dispersions” said Marco Gil, VP Sales at Hovione adding, “Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization, offering the best scale-up science, extensive manufacturing capacity and an excellent approval track record.”   This Global License Agreement is aligned with Hovione’s strategy to offer integrated product solutions for drug delivery that co-create value with its partners and enable the development of innovative medicines that maximize patient benefit.

Hovione Investments

2 Investments

Hovione has made 2 investments. Their latest investment was in Oxular as part of their Series A on February 2, 2016.

CBI Logo

Hovione Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/22/2016

Series A

Oxular

$20.6M

Yes

4

2/22/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2016

2/22/2016

Round

Series A

Series A

Company

Oxular

Subscribe to see more

Amount

$20.6M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

4

10

Hovione Partners & Customers

10 Partners and customers

Hovione has 10 strategic partners and customers. Hovione recently partnered with Ji Xing Pharmaceuticals on May 5, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

5/9/2022

Licensee

China

1

5/9/2022

Licensee

China

Ji Xing Pharmaceuticals Limited. Hovione Signs Exclusive License Agreement With JIXING Hovione Signs Exclusive License Agreement with JIXING.

`` We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione 's leadership position in spray dried dispersions '' said Marco Gil , VP Sales at Hovione adding , `` Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization , offering the best scale-up science , extensive manufacturing capacity and an excellent approval track record . ''

1

5/9/2022

Licensee

China

Hovione Signs Exclusive License Agreement with JIXING

`` We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione 's leadership position in spray dried dispersions '' said Marco Gil , VP Sales at Hovione adding , `` Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization , offering the best scale-up science , extensive manufacturing capacity and an excellent approval track record . ''

1

2/22/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

2/22/2022

Partner

Denmark

Subscribe to see more

Subscribe to see more

10

Date

5/9/2022

5/9/2022

5/9/2022

2/22/2022

2/22/2022

Type

Licensee

Licensee

Licensee

Partner

Partner

Business Partner

Country

China

China

China

United States

Denmark

News Snippet

Ji Xing Pharmaceuticals Limited. Hovione Signs Exclusive License Agreement With JIXING Hovione Signs Exclusive License Agreement with JIXING.

`` We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione 's leadership position in spray dried dispersions '' said Marco Gil , VP Sales at Hovione adding , `` Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization , offering the best scale-up science , extensive manufacturing capacity and an excellent approval track record . ''

Hovione Signs Exclusive License Agreement with JIXING

`` We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione 's leadership position in spray dried dispersions '' said Marco Gil , VP Sales at Hovione adding , `` Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization , offering the best scale-up science , extensive manufacturing capacity and an excellent approval track record . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Hovione Team

1 Team Member

Hovione has 1 team member, including former Senior Director, Roger Viney.

Name

Work History

Title

Status

Roger Viney

Senior Director

Former

Name

Roger Viney

Work History

Title

Senior Director

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.